Cara Therapeutics Q2 EPS $(0.58) Misses $(0.56) Estimate, Sales $6.93M Beat $6.49M Estimate
Portfolio Pulse from vinayak@benzinga.com
Cara Therapeutics reported Q2 losses of $(0.58) per share, missing the analyst consensus estimate of $(0.56) by 3.57%. This is a 625% decrease from the same period last year. However, the company's quarterly sales of $6.93 million beat the analyst consensus estimate of $6.49 million by 6.83%, despite a 69.86% decrease from last year.
August 07, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics' Q2 earnings per share missed estimates, while sales beat expectations. However, both earnings and sales have significantly decreased compared to the same period last year.
Cara Therapeutics' Q2 earnings per share missed the analyst consensus estimate, which could negatively impact investor sentiment and potentially lead to a decrease in the stock price. Additionally, the significant decrease in both earnings and sales compared to the same period last year could further dampen investor sentiment.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100